This Event Has Been Cancelled
Hanson Wade Group have taken the decision to cancel this meeting. Please do accept our apologies for any inconvenience or disappointment this will cause. Please register your interest here if you would like updates on the meeting or topic.
Selecting & Optimising Predictive & Cost-Effective Models to Enhance Target Selection, Facilitate Biomarker Discovery & Achieve Clinical Translatability
2026 is set to reshape the future of preclinical oncology.
As we close out 2025 with the UK accelerating its roadmap to phase out animal testing and SillaJen securing a landmark FDA approval using only organoid efficacy data, the momentum has never been stronger. With immunomodulating therapies surging and preclinical development costs continuing to climb, the pressure is on for biopharma to cut attrition and de-risk every preclinical decision.
The message is clear: investing in more trustworthy, physiologically relevant, and cost-effective models is now mission‑critical for successfully advancing assets worldwide.
Join your peers at the Tumour Models Summit Malmö as the industry's leading minds unite to navigate this paradigm shift and define the future of preclinical oncology.